Financial Daily from THE HINDU group of publications
Saturday, Sep 04, 2004

News
Features
Stocks
Cross Currency
Shipping
Archives
Google

Group Sites

Home Page - Pharmaceuticals
Corporate - Courts/Legal Issues
Industry & Economy - IPR


Novartis' patent held valid; Dr Reddy's withdraws case

Our Bureau

Mumbai , Sept. 3

THE global pharma major, Novartis AG, announced on Friday that it had prevailed in its US patent infringement lawsuit with Dr Reddy's Laboratories Ltd.

The lawsuit pertained to the oral antifungal agent, Lamisil Tablets (terbinafine hydrochloride), a leading prescription drug from Novartis for the treatment of onychomycosis, a fungal infection that discolours, thickens and destroys the nail plate of toenails and fingernails. An estimated 35 million Amercians suffer from onychomycosis.

According to a communiqué from the $24.9-billion Novartis, that was released in Basel, Dr Reddy's had withdrawn its challenge to a Lamisil patent held by Novartis, conceding its validity and admitting that there was an infringement.

"While generics play an important and legitimate role in offering cost-effective therapeutic alternatives, strong patent protection remains essential to fostering continuous innovation that advances medical treatment for patients," said Dr Daniel Vasella, Chairman and CEO, Novartis.

Under the terms of the consent judgment in the US District Court for the Southern District of New York, Dr Reddy's will not manufacture, use, sell or import in the US a generic version of this drug at least until the patent expiry date of December 2006 and any paediatric exclusivity extension (six months) issued by the USFDA for the patent.

Novartis has a strong patent position for Lamisil that relies on evidence showing terbinafine hydrochloride to be a distinctive molecule with a unique mode of action. Both chemically and therapeutically, terbinafine is unique in its class in the treatment of onychomycosis.

Our Hyderabad Bureau adds: Dr Reddy's Laboratories Ltd announced on Friday that it has decided not to pursue further its patent infringement lawsuit against Novartis in a US district court pertaining to terbinafine hydrochloride tablets, the generic version of Novartis' Lamisil, widely prescribed oral antifungal agent with US sales of over $460 million.

Explaining the reason for the shift in its stand on patent infringement strategy for the US generics market, Dr Reddy's said in a press release that the decision was taken because the time needed to obtain a favourable Federal Circuit decision prior to patent expiration would not be met.

While deciding not to pursue further its district court challenge, Dr Reddy's has decided to amend its abbreviated new drug application (ANDA) for terbinafine hydrochloride tablets from a Paragraph-IV Certification to a Paragraph-III Certification on the remaining unexpired Orange Book Patent listed for the drug.

According to Dr Reddy's, though the court had recently granted a bifurcation motion, the court denied Dr Reddy's request to set a trial date.

More Stories on : Pharmaceuticals | Courts/Legal Issues | IPR

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page



Stories in this Section
`Over 1 million jobs in Europe moving out'


Tata Indicom enters wireless pre-paid space with new features
Inflation breaches 8 pc barrier
PM reconstitutes trade, industry council
Govt okays HPCL's tie-up with French co for tech upgradation
Novartis' patent held valid; Dr Reddy's withdraws case
Citroen watching the road to India
LIC, GIC, UTI asked to withdraw funds from SDS — Govt move to cut down interest payouts
Late-hour buying props up Sensex
Bonds rally despite surge in inflation
Good infrastructure vital for attracting FDI: Montek
Delay in funds release hits rural telephony



The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription
Group Sites: The Hindu | Business Line | Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |

Copyright © 2004, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line